Popular
VTRS · Medicine & biotech · U.S.

Viatris

Makes cheaper copies of medicines plus brands like Viagra and Lipitor.

Company Health

32
/100
Weak
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $25 of every $100 in sales.
Is it growing?
5 of 25 · Poor
Sales shrank about 4% a year over the last 3 years.
Can it handle what it owes?
7 of 25 · Poor
It would take about 9 years of the cash its business brings in to pay off everything it owes.
Does it bring in spare cash?
20 of 25 · Good
After paying for buildings and equipment, $14 of every $100 in sales was left as spare cash.

Who owns it

1 of 23 own it · 1 bought more lately
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Viatris’ yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $11.9 billion in 2020 to $14.3 billion in 2025, and it made a profit in 2 of the 6 years.
2025
Sales
$14.3 billion
Loss
$3.51 billion

Spare cash each year

It had cash to spare every year, ending with $1.94 billion to spare in 2025.
2025
Spare cash
$1.94 billion
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $37.2 billion, including $1.32 billion in cash, and owed $22.5 billion.

Key facts

From its yearly report for 2025.
Sales
$14.3 billion
Loss
$3.51 billion
Spare cash
$1.94 billion
Cash in the bank
$1.32 billion
Everything it owes
$22.5 billion
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Feb 26, 2026
Figures from Viatris’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy